← Back to OncoGuides Main Platform
✓ Clinically Audited: August 2026 • OncoGuides Medical Advisory Board
Prostate Cancer: Risk Stratification, Gleason Grading, ARPIs & PSMA Radioligand
Clinical guidelines for localized, castration-sensitive, and metastatic castration-resistant prostate cancer (mCRPC).
1. Overview & Pathophysiology
Prostate cancer is the most common non-cutaneous malignancy in men. Risk stratification for localized disease incorporates serum Prostate-Specific Antigen (PSA), digital rectal examination (clinical T stage), and International Society of Urological Pathology (ISUP) Gleason Grade Groups (1 through 5). Advanced disease management is structured around androgen deprivation therapy (ADT) sensitivity: metastatic castration-sensitive prostate cancer (mCSPC) vs metastatic castration-resistant prostate cancer (mCRPC).
2. Molecular Subtypes & Biomarker Profiling
Key molecular drivers and imaging biomarkers:
- Prostate-Specific Membrane Antigen (PSMA): Overexpressed in >85% of prostate carcinomas; imaged via 68Ga-PSMA-11 or 18F-DCFPyL PET/CT and therapeutically targeted with 177Lu-vipivotide tetraxetan (Pluvicto).
- Homologous Recombination Repair (HRR) Genes: Germline or somatic mutations in BRCA1, BRCA2, ATM, CDK12 occur in ~20–25% of mCRPC; predicts high response rates to PARP inhibitors (Olaparib, Rucaparib, Talazoparib).
- Androgen Receptor Splice Variant 7 (AR-V7): Circulating tumor cell detection predicts primary resistance to enzalutamide and abiraterone, favoring taxane chemotherapy (Docetaxel/Cabazitaxel).
3. Standard-of-Care Treatment Protocols (NCCN/ASCO 2026)
| Disease Setting |
First-Line Systemic / Local Protocol |
Mechanism / Key Benefit |
| Localized High-Risk |
External Beam Radiation (EBRT) + 24–36 months Androgen Deprivation Therapy (ADT) |
LHRH agonist/antagonist (Leuprolide/Relugolix) improves biochemical disease-free survival |
| Metastatic Castration-Sensitive (mCSPC) |
ADT + Androgen Receptor Pathway Inhibitor (ARPI: Enzalutamide, Apalutamide, or Abiraterone) +/- Docetaxel |
Triplet or doublet intensification extends median overall survival beyond 5 years |
| mCRPC (PSMA-PET Positive) |
Lutetium-177 PSMA (177Lu-vipivotide tetraxetan / Pluvicto) 7.4 GBq IV q6w x 6 cycles |
Targeted beta-particle radioligand delivers localized DNA damage to tumor metastases |
4. Supportive Oncology & Organ Comorbidities
Multidisciplinary Supportive Care Links:
Managing therapy-induced organ toxicities is essential for maintaining dose intensity and overall survival:
- Cardiotoxicity & LVEF Monitoring: CardioOncoGuides (Anthracycline & HER2-induced cardiomyopathy).
- Renal Function & Cisplatin AKI: NephroOncoGuides (GFR calculators, TLS & hydration protocols).
- Pulmonary Toxicity & Pneumonitis: PulmonaryOncoGuides (ICI pneumonitis steroid tapers & Bleomycin DLCO).
- Cutaneous Toxicities & EGFR Rash: OncoDermatologyGuides (SCORTEN calculators, doxycycline tapers & scalp cooling).
- Chemotherapy Neuropathy (CIPN): NeuroOncoGuides (Duloxetine titration & cryotherapy).
- Cancer-Related Lymphedema: LymphedemaOncoGuides (Complete Decongestive Therapy CDT).
- Fertility Preservation: OncoFertilityGuides (Oocyte/sperm cryopreservation & GnRH-a).
- Psychosocial Support: PsychoOncoGuides (Distress Thermometer & free psychotherapy grants).
5. Patient & Caregiver Frequently Asked Questions
What is the difference between an LHRH agonist and an LHRH antagonist?
LHRH agonists (e.g., Leuprolide, Goserelin) initially cause a transient testosterone surge before receptor downregulation; LHRH antagonists (e.g., Degarelix, oral Relugolix) immediately suppress pituitary LH release without an initial flare and demonstrate lower cardiovascular event rates.
6. Primary Evidence & Guideline Citations
- Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2026. J Natl Compr Canc Netw. PMID: 33798971.
- Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION). N Engl J Med. 2021;385(12):1091-1103. PMID: 34161051.
- de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer (PROfound). N Engl J Med. 2020;382(22):2091-2102. PMID: 32343890.